CHANDRA BARTHOLOMEUSZ to Female
This is a "connection" page, showing publications CHANDRA BARTHOLOMEUSZ has written about Female.
Connection Strength
0.175
-
Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Sci Rep. 2020 05 22; 10(1):8537.
Score: 0.020
-
MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opin Ther Targets. 2017 09; 21(9):849-859.
Score: 0.016
-
MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Mol Cancer Ther. 2015 Dec; 14(12):2773-81.
Score: 0.014
-
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist. 2012; 17(6):766-74.
Score: 0.011
-
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb; 11(2):360-9.
Score: 0.011
-
PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res. 2010 Mar 15; 16(6):1802-11.
Score: 0.010
-
PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15; 68(22):9302-10.
Score: 0.009
-
Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. 2006 Jan 05; 25(1):79-90.
Score: 0.007
-
Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res. 2005 Sep 15; 65(18):8406-13.
Score: 0.007
-
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Mol Cancer Ther. 2021 02; 20(2):296-306.
Score: 0.005
-
Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. Cells. 2020 02 24; 9(2).
Score: 0.005
-
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.
Score: 0.005
-
c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. Oncogene. 2017 05 04; 36(18):2599-2608.
Score: 0.004
-
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec; 14(12):2687-99.
Score: 0.004
-
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015 Jun; 151(3):501-13.
Score: 0.004
-
HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600.
Score: 0.003
-
Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. Cancer Lett. 2015 Jan 28; 356(2 Pt B):374-381.
Score: 0.003
-
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72.
Score: 0.003
-
Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.
Score: 0.003
-
Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111.
Score: 0.003
-
Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. Oncogene. 2014 Jan 23; 33(4):440-8.
Score: 0.003
-
Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45.
Score: 0.003
-
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65.
Score: 0.003
-
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011 Sep; 122(3):641-7.
Score: 0.003
-
Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol. 2010 Dec; 100(3):449-57.
Score: 0.002
-
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50.
Score: 0.002
-
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77.
Score: 0.002
-
Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther. 2007 Jan; 6(1):227-35.
Score: 0.002
-
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res. 2007; 9(4):R41.
Score: 0.002
-
Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. Cancer Gene Ther. 2006 May; 13(5):451-9.
Score: 0.002
-
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
Score: 0.001
-
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
Score: 0.001